Who are Xencor, Inc.'s main suppliers?

Xencor, Inc. (XNCR) key suppliers include: KBI-BIOPHARMA-INC, OMERS, INCYTE. View the full supplier network at chainsifter.com/chain/XNCR.

Who are Xencor, Inc.'s major customers?

Xencor, Inc. (XNCR) key customers include: Gilead Sciences, Inc., Gilead Sciences, Inc., Johnson & Johnson, Johnson & Johnson, Novartis AG and 14 more. View the full customer network at chainsifter.com/chain/XNCR.

What sector is Xencor, Inc. in?

Xencor, Inc. (XNCR) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Xencor, Inc. Suppliers, Customers & Supply Chain (XNCR)

3Suppliers

19Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Xencor, Inc. (XNCR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

26Total relationships

4Distinct source URLs

7High confidence

0.746Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Xencor, Inc. Suppliers

Ticker	Name	Confidence	Evidence
KBI-BIOPHARMA-INC	KBI-BIOPHARMA-INC	92%	We have engaged KBI under the KBI Agreement for process development, clinical scale-up, analytical method development, formulation development, and other services related to drug substance and drug p…
OMERS	OMERS	90%	Pursuant to the Monjuvi Royalty Sale Agreement and subject to the Company’s existing license with Incyte, OMERS acquired the right to receive up to $ 29.3 million in royalties earned after July 1, 20…
INCYTE	INCYTE	80%	Pursuant to the Monjuvi Royalty Sale Agreement and subject to the Company’s existing license with Incyte, OMERS acquired the right to receive up to $ 29.3 million in royalties earned after July 1, 20…

Xencor, Inc. Customers

Ticker	Name	Confidence	Evidence
GILD	Gilead Sciences, Inc.	72%	these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of December 31, 2025, the outstanding letter of cr…
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from XNCR graph: these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Sig…
JNJ	Johnson & Johnson	72%	Reciprocal relationship from JNJ graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from JNJ grap…
JNJ	Johnson & Johnson	72%	these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of December 31, 2025, the outstanding letter of cr…
NVSEF	Novartis AG	72%	Reciprocal relationship from NVSEF graph: Reciprocal relationship from XNCR graph: these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Si…
NVSEF	Novartis AG	72%	these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of December 31, 2025, the outstanding letter of cr…
TECH	Bio-Techne Corporation	72%	Reciprocal relationship from TECH graph: Reciprocal relationship from XNCR graph: old 8,093,712 shares of our common stock at the public offering price of $18.00 per share, which included the exercis…
TECH	Bio-Techne Corporation	72%	old 8,093,712 shares of our common stock at the public offering price of $18.00 per share, which included the exercise in full by the underwriters of their option to purchase 1,458,600 shares of our …
VIR	Vir Biotechnology, Inc.	72%	Reciprocal relationship from VIR graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from VIR graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from VIR grap…
VIR	Vir Biotechnology, Inc.	72%	these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of December 31, 2025, the outstanding letter of cr…
VRDN	Viridian Therapeutics, Inc.	72%	Reciprocal relationship from VRDN graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from VRDN graph: Reciprocal relationship from XNCR graph: these consolidated financial statem…
VRDN	Viridian Therapeutics, Inc.	72%	these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of December 31, 2025, the outstanding letter of cr…
ZBIO	Zenas BioPharma, Inc.	72%	Reciprocal relationship from ZBIO graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from ZBIO graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from ZBIO g…
ZBIO	Zenas BioPharma, Inc.	72%	these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidated Financial Statements 1. Summary of Significant Accounting Policies As of December 31, 2025, the outstanding letter of cr…
AIMMUNE-THERAPEUTICS-INC	AIMMUNE-THERAPEUTICS-INC	62%	s to evaluate XmAb drug candidates. 2. Build and manage a pipeline of XmAb drug candidates. We advance multiple XmAb drug candidates into early stages of clinical development and evaluate data from s…
BIOMEDICAL-RESEARCH-INC	BIOMEDICAL-RESEARCH-INC	62%	, we earned $0.6 million in royalties from Vir. In June 2016, we entered into an agreement with Novartis Institutes for BioMedical Research, Inc. in which we provided Novartis with a non-exclusive li…
INMB	INmune Bio Inc.	62%	Reciprocal relationship from INMB graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from INMB graph: Reciprocal relationship from XNCR graph: Reciprocal relationship from INMB g…
MORPHOSYS-AG	MORPHOSYS-AG	62%	( 1,546 ) XmAb808 (B7-H3 x CD28) 546 ( 2,196 ) Other programs including research and early stage ( 5,086 ) ( 2,092 ) Wind down costs of terminated programs ( 1,145 ) ( 7,655 ) Internal research and d…
SVB-SECURITIES-LLC	SVB-SECURITIES-LLC	62%	future payments for U.S. sales. The Company has applied the variable consideration constraint under ASC 606 and constrained U.S. royalty revenue to zero pending resolution of the dispute. 13 Table of…

Xencor, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
XNCR-DEBT	Debt stack $104.9M	90%	Market cache reports total debt of $104.9M.
XNCR-DEBT-13669	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2013-12-31.
XNCR-DEBT-13668	Warrants outstanding: 0.01	90%	xbrl warrant detail from xbrl 2024-09-30.

Xencor, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Xencor, Inc..

Xencor, Inc. Ownership

Holder	Name	Confidence	Evidence
XNCR-OWNER-BLACKROCK-INC	BlackRock, Inc.	90%	13F overlay lists BlackRock, Inc. as top holder; 206 tracked holders.

Xencor, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops
ALC	Alcon Inc.	100.00	2
CLGN	CollPlant Biotechnologies Ltd.	100.00	2
AZN	AstraZeneca PLC	100.00	2
SNNUF	Smith & Nephew plc	100.00	2
BHC	Bausch Health Companies Inc.	100.00	2
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
AVIR	Atea Pharmaceuticals, Inc.	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
CSTE	Caesarstone Ltd.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
ATRA	Atara Biotherapeutics, Inc.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
CYTOF	Altamira Therapeutics Ltd.	100.00	2
DNTH	Dianthus Therapeutics, Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
CABA	Cabaletta Bio, Inc.	100.00	2

Xencor, Inc. Supply Chain